Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15. SPC-15 is an intranasal therapeutic targeting post-traumatic stress disorder (PTSD). The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” includes composition and method claims. This development expands Silo’s intellectual property portfolio in stress-modulating therapeutics within a key international market, with management noting the allowance supports protection of the company’s core scientific innovations ahead of formal patent grant.
The patent allowance in Japan is significant for Silo Pharma as it provides a competitive edge in a region with a growing demand for mental health treatments. PTSD is a debilitating condition affecting millions worldwide, and the need for effective therapies is urgent. SPC-15, designed for intranasal administration, aims to prevent stress-induced fear, depression-like behavior, and anxiety-like behavior. The intranasal route of delivery may offer advantages such as rapid onset of action and ease of use, potentially improving patient compliance. Silo Pharma’s focus on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, positions it to address significant unmet medical needs.
The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo conducts its research in collaboration with leading universities and laboratories. The patent allowance in Japan is a milestone that may enhance the company’s valuation and attract potential partners or investors. It also demonstrates the company’s commitment to protecting its intellectual property globally. For more information, the full press release is available at https://ibn.fm/UB47M. Silo Pharma’s newsroom can be accessed at https://ibn.fm/SILO.
